CNSL

Cambridge Nutritional Sciences PLC

Health Care First-pass screen £4.76m

420/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 60

Valuation 25% 32

Downside protection 15% 70

First-pass take

No AI exposure evident in detailed disclosure; medical diagnostics focused on food sensitivity testing. Operational efficiency shown (EBITDA +115% on cost discipline), but thin adjusted margins (£42k on £8.3m revenue, 0.5%) and negative free cash flow when excluding one-time £2.5m DHSC settlement. Micro-cap with net cash provides downside protection but lacks valuation appeal.

Flags

no-ai-exposureno-valuation-datathin-marginsmicro-capnegative-fcfgrowth-challengedtransformation-phase